MDM2 and cancer: Utilizing a novel first-in-class cell-penetrating peptide disruptor of MDM2 homo- and heterodimerization (DRx-098D), we demonstrate the anti-proliferative potential of blocking MDM2 dimerization against a panel of human cancer cell lines that are TP53 wild type, mutant, or null.